enGene expands debt facility with Hercules to $125M, $25M funded to refinance existing debt

enGene Therapeutics Inc.

Up to $125M debt facility from Hercules Capital; $25M funded at closing to refinance existing debt.
Three additional tranches up to $75M available upon achieving clinical, regulatory, and commercial milestones; final $25M at Hercules' discretion.
Maturity date January 1, 2030; proceeds support detalimogene BLA filing in H2 2026 and potential launch in 2027.
Non-dilutive capital strengthens balance sheet for planned BLA in BCG-unresponsive NMIBC with carcinoma in situ.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.